SynthesisGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2026
Oral therapeutic interventions for central serous chorioretinopathy: A systematic review.
Synthesis in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeCentral serous chorioretinopathy (CSCR) is characterized by serous neurosensory retinal detachment that predominantly affects working-age men. Many acute cases resolve spontaneously, but chronic or recurrent forms can lead to permanent visual impairment. Oral pharmacological therapies have emerged as a noninvasive alternative to photodynamic therapy (PDT), particularly in the context of verteporfin shortage. This systematic review aims to evaluate the efficacy of oral agents for CSCR, focusing on subretinal fluid (SRF), best-corrected visual acuity (BCVA), choroidal thickness, and recurrence.
methodsFollowing PRISMA 2020 guidelines, we searched MEDLINE, the Cochrane Library, and Web of Science (January 1990 to May 2025) for randomized controlled trials (RCTs) assessing oral therapies for CSCR. Risk of bias was assessed using the Cochrane RoB 2.
resultsOur search returned 14 trials that met our inclusion criteria. We found that mineralocorticoid receptor antagonists appeared to reduce SRF in most studies (6 of 8 trials), while their effects on BCVA and choroidal thickness were inconsistent. Helicobacter pylori eradication therapy showed no significant SRF reduction or effects on BCVA compared to placebos or control group. Propranolol improved both complete SRF resolution and BCVA, while metipranolol demonstrated no significant effects. Due to high heterogeneity between studies, we did not perform a meta-analysis.
conclusionMineralocorticoid receptor antagonists may reduce SRF in CSCR, although visual outcomes remain uncertain. Propranolol may offer potential benefit based on limited evidence. Other oral therapies lack supportive evidence. Given study heterogeneity and absence of meta-analysis, findings should be interpreted with caution. Further large-scale RCTs are needed.
Indexed as
Identifiers
42043512What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.